Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. | Prognostic role of CD4 T-cell depletion after frontline fludarabine cyclophosphamide and rituximab in chronic lymphocytic leukaemia